Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9799773 | 0.78 | ALDH1A1 (0.44) | ALDH1A1KDM4ETDP1MAPTHTT | |
| SCHEMBL14607679 | 0.78 | ALDH1A1 (0.40) | ALDH1A1MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL4891409 | 0.76 | LTA4H (0.45) | ALDH1A1KDM4ETDP1MAPTHTT | |
| SCHEMBL14573950 | 0.74 | CRHBP (0.35) | ALDH1A1 | |
| Cyclopropane SCHEMBL7531022 | 0.69 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL28408773 | 0.69 | MAPT (0.39) | ALDH1A1KDM4ETDP1MAPTHTT | |
| SCHEMBL346747 | 0.66 | HRH3 (0.43) | ALDH1A1KDM4EMAPTL3MBTL1HRH3 | |
| SCHEMBL8670408 | 0.65 | HRH3 (0.47) | ALDH1A1KDM4ETDP1MAPTHTT | |
| SCHEMBL797426 | 0.64 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTHTTHRH3 | |
| SCHEMBL9803653 | 0.64 | ALDH1A1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338118-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2013-12-19 | — | — | US | claimed |
| EP-2665472-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | Solvotrin Innovations Limited (IE) | 2013-11-27 | — | — | EP | claimed |
| WO-2012076667-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2012-06-14 | — | — | WO | claimed |
| EP-2665472-B1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LTD (IE) | 2022-07-06 | — | — | EP | disclosed |
| US-9566342-B2 | Compounds for treatment of heart failure | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2017-02-14 | — | — | US | disclosed |
| US-20130338118-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2013-12-19 | — | — | US | disclosed |
| EP-2665472-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | Solvotrin Innovations Limited (IE) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012076667-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338118-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | MMP9, NOS2, MMP1 | ALDH1A1 2466/4885KDM4E 2021/4885TDP1 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.